What immune response did lower-dose shots show in children aged 6 months?

Question

Accepted Answer

Lower-Dose Covid-19 Vaccine Shots Showed Strong Immune Response in Young Children

Pfizer and BioNTech have submitted data to the US Food and Drug Administration indicating that three lower-dose shots of their Covid-19 vaccine elicited a robust immune response in children as young as six months old. This filing seeks authorisation for the vaccine's use in children under five years of age.
Filing for Authorisation Completed

Pfizer and its partner BioNTech have finalised their submission to the US drugs regulator. This action is specifically aimed at obtaining authorisation for the administration of their Covid-19 vaccine to children aged under five.
Data on Immune Response in Infants

The submitted data demonstrates the efficacy of a three-dose regimen of the vaccine. These lower-dose shots were shown to produce a significant immune response in infants and young children, starting from the age of six months.
Focus on Under-Five Age Group

The regulatory filing by Pfizer and BioNTech specifically targets the youngest demographic, children under five years old. This move aims to expand vaccination access to this age group, for whom the vaccine may not have been previously authorised.

Reading history

Hide →

This history is cleared when the page is closed.

What immune response did lower-dose shots show in children aged 6 months?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends